Ozempic Medicaid Coverage by State Tier (2026 Guide)

Print or save as PDFOpens the printable coverage checklist and your print dialog. No sign-up.

Is there one national Medicaid tier for Ozempic?

No. Medicaid coverage is decided state by state, and each state's preferred drug list sets its own tiers, prior-authorization criteria and cost sharing. No state table appears below because 2026 placements for Ozempic could not be confirmed.

What the Ozempic label covers

Ozempic is a once-weekly subcutaneous GLP-1 receptor agonist approved on December 5, 2017 under NDA 209637 [2][1]. The label effective June 1, 2026 lists three indications, all in adults with type 2 diabetes: glycemic control as an adjunct to diet and exercise; reduced risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) with established cardiovascular disease; and reduced risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death with chronic kidney disease [1].

The label lists 0.25 mg once weekly for the first 4 weeks as the starting dose, followed by 0.5 mg once weekly. Maintenance doses are 0.5 mg, 1 mg or 2 mg once weekly, with increases after at least 4 weeks on the current dose; 2 mg weekly is the maximum [1].

Weight loss and compounded semaglutide

The Ozempic label carries no weight-loss indication [1]. Wegovy has its own FDA approval, NDA 215256, granted on June 4, 2021, and its own prescribing information [3].

FDA says compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [4]. FDA also says the period during which it tolerated shortage-based compounding of semaglutide injection has ended [5].